Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS

lesturner Foundation Blog, Home Page, Research & The Les Turner ALS Center

We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020)  in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …

Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression

lesturner Foundation Blog, Home Page, Research & The Les Turner ALS Center

We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …